Please try another search
For the three months ended 31 March 2021, AlexionPharmaceuticals, Inc. revenues increased 13% to $1.64B. Netincome increased 14% to $636M. Revenues reflect ULTOMIRISsegment increase of 56% to $346.9M, Strensiq segmentincrease of 15% to $197.5M. Net income benefited fromAcquisition-related costs decrease of 65% to $13.2M(expense), Amortization of purchased intangible assdecrease of 28% to $53.2M (expense).
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 1636.5 | 1591.8 | 1588.7 | 1444.6 |
Gross Profit | 1511.1 | 1439.6 | 1444 | 1299.7 |
Operating Income | 636.2 | 622.1 | 684.9 | -1370.2 |
Net Income | 636 | 535.8 | 578.1 | -1068.1 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 18650.2 | 18103 | 17548.4 | 16703.2 |
Total Liabilities | 6233.4 | 6451.8 | 6473.5 | 6212.4 |
Total Equity | 12416.8 | 11651.2 | 11074.9 | 10490.8 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 637.6 | 3002.9 | 2162.4 | 1339.6 |
Cash From Investing Activities | -133.9 | -2099.5 | -2018.9 | -751.5 |
Cash From Financing Activities | -18.7 | -611.9 | -538.1 | -430.7 |
Net Change in Cash | 471.9 | 311 | -395.1 | 149.3 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review